Methods And Compositions For Treating Infections

Abstract

The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of DC-SIGN+ dendritic cells in very early phases of viral infections. By using four anti-human DC-SIGN monoclonal antibodies, the inventors have demonstrated that DC-SIGN might be considered as the most important receptor for both pre- and post-fusion HCMV gB on monocyte-derived dendritic cells (MDDCs). In particular, the invention relates to a method for treating an infection in a subject in need thereof comprising a step of administering to said subject an agent that blocks the interaction between DC-SIGN and an infectious ligand.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jul 26, 2018
  • Application: Jan 22, 2018
    WO EP 2018051406 W
  • Priority: Jan 23, 2017
    EP EP 17305064 A

Download Citation


Sign in to the Lens

Feedback